Drug Profile


Alternative Names: Capoxigem; CS-706; Kymena; R-109339; TG 01; TP1001 programme; TP2001 programme

Latest Information Update: 06 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Tragara Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Inflammation; Inflammatory pain; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 09 Jul 2015 Tragara Pharmaceuticals completes a phase II trial in Non-small cell lung cancer (Combination therapy, late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT00771953)
  • 07 Jun 2011 Final efficacy data from the phase II APRiCOT-L trial in recurrent late-stage or metastatic Non-small cell lung cancer (second-line therapy, in combination with erlotinib) presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO-2011)
  • 26 May 2011 Pharmacodynamics data from animal studies in solid tumours released by Tragara Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top